Drugs / ABT-751
ABT-751
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00047489 | Dec 2002 → Jan 2005 | hematopoietic and lymphoid cell neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT00036959 | Mar 2002 → Feb 2010 | central nervous system neoplasm, childhood germ cell tumor, childhood malignant neoplasm, extragonadal germ cell tumor +5 | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT00439296 | May 2006 → May 2009 | childhood acute lymphoblastic leukemia | Therapeutic Advances in Childhood Leukemia Consortium | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00735878 | Sep 2004 → Jan 2009 | non-small cell lung carcinoma | Konstantin Dragnev | Terminated | No outcome recorded |
| Phase 1/2 | NCT00471718 | Jan 2004 → Aug 2009 | prostate cancer | Vanderbilt-Ingram Cancer Center | Terminated | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT00436852 | Jan 2007 → Sep 2010 | neuroblastoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00073151 | Sep 2003 → Jan 2006 | non-small cell lung carcinoma | Abbott | Completed | No outcome recorded |
| Phase 2 | NCT00073112 | Aug 2003 → Sep 2006 | renal cell carcinoma | Abbott | Completed | No outcome recorded |
| Phase 2 | NCT00073138 | Aug 2003 → Feb 2005 | colorectal cancer | Abbott | Completed | No outcome recorded |
| Phase 2 | NCT00063102 | Nov 2002 → Aug 2004 | breast cancer | Abbott | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT00354562 Comparator | Feb 2007 → Feb 2008 | non-small cell lung carcinoma | Abbott | Terminated | No outcome recorded |
| Phase 1/2 | NCT00297089 Comparator | Nov 2006 → Jan 2009 | non-small cell lung carcinoma | AbbVie | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABT-751 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00073112 ↗ |
| Known as | E 7010 | ChEMBL registry synonym — accepted as the source's own label CHEMBL20684 ↗ |
| Known as | NSC-742134 | ChEMBL registry synonym — accepted as the source's own label CHEMBL20684 ↗ |
| Action | Inhibit | “ABT-751 is a novel orally administered antimitotic agent that binds to the colchicine site on beta-tubulin and inhibits polymerization of microtubules.” NCT00047489 ↗ |
| Modality | Other / unclassified | “antimitotic and vascular disrupting agent” PMID 21300929 ↗ Feb 2011 |
| Route | Oral | “ABT-751 administered orally once daily for 21 days” PMID 18281544 ↗ Feb 2008 |